FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021127595> ?p ?o ?g. }

• W2021127595 endingPage "S360" @default.
• W2021127595 startingPage "S360" @default.
• W2021127595 abstract "To report clinical outcomes and toxicities in hormone refractory, oligometastatic (<5 lesions) prostate patients treated with stereotactic body radiation therapy (SBRT) enrolled in a prospective registry. Twenty-one lesions in 17 patients confirmed by choline-PET (n = 7), MRI (n = 6), biopsy (n = 1), CT (n = 1), and both choline-PET/MRI (n = 2) were treated with SBRT between February 2009 and November 2011. Sites of treatment included bone (n = 19), lymph nodes (n = 1), and liver (n = 1). Median age of patients was 65.5 (range, 51-79.5). Patients underwent CT simulation with Body Fix immobilization. Target volume was defined with MRI and/or PET fusion, and daily image-guidance. Median dose prescribed was 24 Gy (range, 18-60 Gy) in a median of 1 fraction (range, 1-5). Post-SBRT evaluation included history and physical examination, PSA testing, and imaging studies every 2-3 months. Local failure was defined by RECIST criteria v1.1 and overall survival (OS) with Kaplan-Meier. Toxicity was graded using CTCAE v3.0. At a median follow-up of 6 months (range, 2-24 months), no local failure was noted in 20 evaluable lesions. PSA data was available for 17 patients, and 8 (47%) patients reached undetectable levels. With the exception of two patients who experienced distant failure, the remaining patients had a downward trend in PSA. Median PSA prior to treatment was 2.1 with an initial post-SBRT median PSA of 0.58 (p < 0.001), and a median PSA of 0.17 (p < 0.001) at the most recent follow up. One and two-year prostate cancer specific survival was 100% and 60%, respectively. Two patients died due to progression of prostate cancer. Distant control rates were 74% at 6 months and 40% at 1 year. Toxicities included one case each of grade 2 dyspnea and grade 2 back pain. We report excellent local control with SBRT in hormone refractory, oligometastatic prostate patients. More significantly, corresponding decreases in PSA were noted to undetectable levels in 47% of patients. Further follow up is necessary to assess the impact of SBRT on local control, toxicity, and PSA-response duration." @default.
• W2021127595 created "2016-06-24" @default.
• W2021127595 creator A5040197178 @default.
• W2021127595 creator A5048628138 @default.
• W2021127595 creator A5062612957 @default.
• W2021127595 creator A5079400879 @default.
• W2021127595 date "2012-11-01" @default.
• W2021127595 modified "2023-09-25" @default.
• W2021127595 title "Role of Stereotactic Body Radiation Therapy in Oligometastatic, Hormone Refractory Prostate Cancer" @default.
• W2021127595 doi "https://doi.org/10.1016/j.ijrobp.2012.07.950" @default.
• W2021127595 hasPublicationYear "2012" @default.
• W2021127595 type Work @default.
• W2021127595 sameAs 2021127595 @default.
• W2021127595 citedByCount "0" @default.
• W2021127595 crossrefType "journal-article" @default.
• W2021127595 hasAuthorship W2021127595A5040197178 @default.
• W2021127595 hasAuthorship W2021127595A5048628138 @default.
• W2021127595 hasAuthorship W2021127595A5062612957 @default.
• W2021127595 hasAuthorship W2021127595A5079400879 @default.
• W2021127595 hasBestOaLocation W20211275951 @default.
• W2021127595 hasConcept C121332964 @default.
• W2021127595 hasConcept C121608353 @default.
• W2021127595 hasConcept C126322002 @default.
• W2021127595 hasConcept C126838900 @default.
• W2021127595 hasConcept C126894567 @default.
• W2021127595 hasConcept C142424586 @default.
• W2021127595 hasConcept C2776235491 @default.
• W2021127595 hasConcept C2780192828 @default.
• W2021127595 hasConcept C2780387249 @default.
• W2021127595 hasConcept C2989005 @default.
• W2021127595 hasConcept C509974204 @default.
• W2021127595 hasConcept C71924100 @default.
• W2021127595 hasConcept C87355193 @default.
• W2021127595 hasConceptScore W2021127595C121332964 @default.
• W2021127595 hasConceptScore W2021127595C121608353 @default.
• W2021127595 hasConceptScore W2021127595C126322002 @default.
• W2021127595 hasConceptScore W2021127595C126838900 @default.
• W2021127595 hasConceptScore W2021127595C126894567 @default.
• W2021127595 hasConceptScore W2021127595C142424586 @default.
• W2021127595 hasConceptScore W2021127595C2776235491 @default.
• W2021127595 hasConceptScore W2021127595C2780192828 @default.
• W2021127595 hasConceptScore W2021127595C2780387249 @default.
• W2021127595 hasConceptScore W2021127595C2989005 @default.
• W2021127595 hasConceptScore W2021127595C509974204 @default.
• W2021127595 hasConceptScore W2021127595C71924100 @default.
• W2021127595 hasConceptScore W2021127595C87355193 @default.
• W2021127595 hasIssue "3" @default.
• W2021127595 hasLocation W20211275951 @default.
• W2021127595 hasOpenAccess W2021127595 @default.
• W2021127595 hasPrimaryLocation W20211275951 @default.
• W2021127595 hasRelatedWork W1544952821 @default.
• W2021127595 hasRelatedWork W1980188241 @default.
• W2021127595 hasRelatedWork W1980245127 @default.
• W2021127595 hasRelatedWork W1982816235 @default.
• W2021127595 hasRelatedWork W2106003470 @default.
• W2021127595 hasRelatedWork W2127440557 @default.
• W2021127595 hasRelatedWork W2321033326 @default.
• W2021127595 hasRelatedWork W2590008096 @default.
• W2021127595 hasRelatedWork W2897445903 @default.
• W2021127595 hasRelatedWork W3029905168 @default.
• W2021127595 hasVolume "84" @default.
• W2021127595 isParatext "false" @default.
• W2021127595 isRetracted "false" @default.
• W2021127595 magId "2021127595" @default.
• W2021127595 workType "article" @default.